Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.5927
-0.0207 (-3.37%)
At close: Feb 12, 2026, 4:00 PM EST
0.5927
0.00 (0.00%)
Pre-market: Feb 13, 2026, 4:38 AM EST
Aprea Therapeutics Employees
Aprea Therapeutics had 8 employees as of December 31, 2024. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
$61,030
Profits / Employee
-$1,629,842
Market Cap
4.15M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 8 | 1 | 14.29% |
| Dec 31, 2023 | 7 | -2 | -22.22% |
| Dec 31, 2022 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| GeoVax Labs | 17 |
| Genprex | 13 |
| Indaptus Therapeutics | 7 |
| Acurx Pharmaceuticals | 4 |
| Matinas BioPharma Holdings | 3 |
| Silo Pharma | 3 |
| Decoy Therapeutics | 2 |
| Cyclerion Therapeutics | 1 |
APRE News
- 20 hours ago - Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth - GlobeNewsWire
- 8 days ago - Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor - GlobeNewsWire
- 14 days ago - Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan - GlobeNewsWire
- 14 days ago - Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 - GlobeNewsWire
- 2 months ago - Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 3 months ago - Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update - GlobeNewsWire
- 3 months ago - Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051 - GlobeNewsWire